Status:
UNKNOWN
Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Helicobacter Pylori Infection
Helicobacter Gastritis
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The hypothesis and plan of the current study are: 1. One induction phase of high dose PPI before eradication will increase intragastric pH and induce H. pylori into an active replicative status. Acti...
Detailed Description
This study aims to evaluate: 1. the first line H. pylori eradication rate of high dose dual therapy with 14 days rabeprazole 20 mg qid, plus amoxicillin 500 mg qid (HDDT group) comparing to the clari...
Eligibility Criteria
Inclusion
- The source of subjects may include (1) community participants who obtain a positive result of urea breath test (UBT) from the checkup screening (2) hospital patients who obtain a positive result of H. pylori infection by esophagogastroduodenoscopy (EGD).
Exclusion
- Exclusion criteria include age less than 20 years, pregnancy or nursing, serious concomitant illness, malignant tumors, history of hypersensitivity to study drugs, active ulcer bleeding, previous gastric surgeries, and taking PPIs within two weeks or antibiotics within one month before study.
Key Trial Info
Start Date :
January 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
530 Patients enrolled
Trial Details
Trial ID
NCT03802318
Start Date
January 2 2019
End Date
December 1 2020
Last Update
January 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang-Gung memorial hospital at Keelung
Keelung, Taiwan, 20401